Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 11, 2016
Boasting a price of $6.94, Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) traded -1.00% lower on the day. With the last close down -11.94% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Nabriva Therapeutics AG – ADR has recorded a 50-day average of $7.47 and a two hundred day average of $7.88. Volume of trade was up over the average, with 17,572 shares of NBRV changing hands over the typical 10,057
Zacks Investment Research has downgraded Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) to Hold in a statement released on Wednesday October 12, 2016.
With a total market value of $0, Nabriva Therapeutics AG – ADR has with a one year low of $6.61 and a one year high of $10.69 .
More About Nabriva Therapeutics AG – ADR (NASDAQ:NBRV)
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.